Peter Dudek
President at Merck Research Ventures
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Hong I. Wan | M | - |
Tallac Therapeutics, Inc.
 Tallac Therapeutics, Inc. BiotechnologyHealth Technology Tallac Therapeutics, Inc. engages in the development of immunomodulating polynucleotides. The company is headquartered in Burlingame, CA. | - |
| Scott Clarke | M | - |
Ambagon Therapeutics, Inc.
 Ambagon Therapeutics, Inc. BiotechnologyHealth Technology Ambagon Therapeutics, Inc. provides healthcare services. It specializes in biotechnology. The company is headquartered in San Francisco, CA. | 3 years |
| Michelle Arkin | F | - |
Ambagon Therapeutics, Inc.
Ambagon Therapeutics, Inc. BiotechnologyHealth Technology Ambagon Therapeutics, Inc. provides healthcare services. It specializes in biotechnology. The company is headquartered in San Francisco, CA. | - |
| Jaume Pons | M | 58 |
Tallac Therapeutics, Inc.
Tallac Therapeutics, Inc. BiotechnologyHealth Technology Tallac Therapeutics, Inc. engages in the development of immunomodulating polynucleotides. The company is headquartered in Burlingame, CA. | - |
| Christine Brennan | M | 56 |
Merck Research Ventures
 Merck Research Ventures Investment ManagersFinance Merck Research Ventures (Merck Research) is a venture capital subsidiary of Merck Research Laboratories Massachusetts LLC founded in 2000. The firm is headquartered in Cambridge, Massachusetts.
Tallac Therapeutics, Inc.
Tallac Therapeutics, Inc. BiotechnologyHealth Technology Tallac Therapeutics, Inc. engages in the development of immunomodulating polynucleotides. The company is headquartered in Burlingame, CA. | 6 years |
| Martin D. Williams | M | 58 |
Caraway Therapeutics, Inc.
 Caraway Therapeutics, Inc. BiotechnologyHealth Technology Caraway Therapeutics, Inc. provides heathcare services. The company was founded by Timothy Harris, Wade Harper ,Ivan Dikic ,Tony Hyman and is headquartered in Cambridge, MA. | - |
| Magdalene M. Moran | M | - |
Caraway Therapeutics, Inc.
Caraway Therapeutics, Inc. BiotechnologyHealth Technology Caraway Therapeutics, Inc. provides heathcare services. The company was founded by Timothy Harris, Wade Harper ,Ivan Dikic ,Tony Hyman and is headquartered in Cambridge, MA. | - |
| Katie Fanning | F | - |
Mozart Therapeutics, Inc.
 Mozart Therapeutics, Inc. BiotechnologyHealth Technology Mozart Therapeutics, Inc. is a company focused on developing first-in-class disease-modifying therapies for autoimmune and inflammatory diseases, with a therapeutic focus on autoimmune mediated gastro-intestinal disorders. The company is based in Seattle, WA. The company utilizes a novel approach to restoring immune system function by targeting the CD8 T regulatory network. Mozart Therapeutics is advancing a pipeline of first-in-class ‘CD8 Treg modulators’ designed to restore durable immune balance. The CEO of the company is Katie Fanning. | - |
| Christian Ottmann | M | - |
Ambagon Therapeutics, Inc.
Ambagon Therapeutics, Inc. BiotechnologyHealth Technology Ambagon Therapeutics, Inc. provides healthcare services. It specializes in biotechnology. The company is headquartered in San Francisco, CA. | - |
| Lucio Iannone | M | 41 |
Mozart Therapeutics, Inc.
Mozart Therapeutics, Inc. BiotechnologyHealth Technology Mozart Therapeutics, Inc. is a company focused on developing first-in-class disease-modifying therapies for autoimmune and inflammatory diseases, with a therapeutic focus on autoimmune mediated gastro-intestinal disorders. The company is based in Seattle, WA. The company utilizes a novel approach to restoring immune system function by targeting the CD8 T regulatory network. Mozart Therapeutics is advancing a pipeline of first-in-class ‘CD8 Treg modulators’ designed to restore durable immune balance. The CEO of the company is Katie Fanning. | 3 years |
| Danilchanka Olga | M | - |
Merck Research Ventures
Merck Research Ventures Investment ManagersFinance Merck Research Ventures (Merck Research) is a venture capital subsidiary of Merck Research Laboratories Massachusetts LLC founded in 2000. The firm is headquartered in Cambridge, Massachusetts. | 6 years |
| Michael Ross | M | 75 |
Xilio Therapeutics LLC
 Xilio Therapeutics LLC Pharmaceuticals: MajorHealth Technology Part of Xilio Therapeutics, Inc., Xilio Therapeutics LLC develops cancer biopharmaceuticals. The company is based in Waltham, MA. The CEO of the company is René Russo. | 4 years |
| Isaac Cheng | M | - |
Tallac Therapeutics, Inc.
Tallac Therapeutics, Inc. BiotechnologyHealth Technology Tallac Therapeutics, Inc. engages in the development of immunomodulating polynucleotides. The company is headquartered in Burlingame, CA. | - |
| Jason R. Ruth | M | 39 |
Merck Research Ventures
Merck Research Ventures Investment ManagersFinance Merck Research Ventures (Merck Research) is a venture capital subsidiary of Merck Research Laboratories Massachusetts LLC founded in 2000. The firm is headquartered in Cambridge, Massachusetts. | - |
| Andy Kadlec | M | - |
InduPro, Inc.
 InduPro, Inc. BiotechnologyHealth Technology InduPro, Inc. engages in integrating inherent protein proximity at the cell surface and translates biological insights into transformative therapeutics. The company is based in San Francisco, CA. The company was founded by K. Christopher Garcia. | - |
| Julie Gilmore | M | - |
Mozart Therapeutics, Inc.
Mozart Therapeutics, Inc. BiotechnologyHealth Technology Mozart Therapeutics, Inc. is a company focused on developing first-in-class disease-modifying therapies for autoimmune and inflammatory diseases, with a therapeutic focus on autoimmune mediated gastro-intestinal disorders. The company is based in Seattle, WA. The company utilizes a novel approach to restoring immune system function by targeting the CD8 T regulatory network. Mozart Therapeutics is advancing a pipeline of first-in-class ‘CD8 Treg modulators’ designed to restore durable immune balance. The CEO of the company is Katie Fanning. | - |
| Sarah Hymowitz | M | - |
InduPro, Inc.
InduPro, Inc. BiotechnologyHealth Technology InduPro, Inc. engages in integrating inherent protein proximity at the cell surface and translates biological insights into transformative therapeutics. The company is based in San Francisco, CA. The company was founded by K. Christopher Garcia. | - |
| Jan Beck | M | - |
Mozart Therapeutics, Inc.
Mozart Therapeutics, Inc. BiotechnologyHealth Technology Mozart Therapeutics, Inc. is a company focused on developing first-in-class disease-modifying therapies for autoimmune and inflammatory diseases, with a therapeutic focus on autoimmune mediated gastro-intestinal disorders. The company is based in Seattle, WA. The company utilizes a novel approach to restoring immune system function by targeting the CD8 T regulatory network. Mozart Therapeutics is advancing a pipeline of first-in-class ‘CD8 Treg modulators’ designed to restore durable immune balance. The CEO of the company is Katie Fanning. | 2 years |
| Marie-Claire Peakman | F | - |
Mozart Therapeutics, Inc.
Mozart Therapeutics, Inc. BiotechnologyHealth Technology Mozart Therapeutics, Inc. is a company focused on developing first-in-class disease-modifying therapies for autoimmune and inflammatory diseases, with a therapeutic focus on autoimmune mediated gastro-intestinal disorders. The company is based in Seattle, WA. The company utilizes a novel approach to restoring immune system function by targeting the CD8 T regulatory network. Mozart Therapeutics is advancing a pipeline of first-in-class ‘CD8 Treg modulators’ designed to restore durable immune balance. The CEO of the company is Katie Fanning. | 1 years |
| Janwillem Naesens | M | - |
Ambagon Therapeutics, Inc.
Ambagon Therapeutics, Inc. BiotechnologyHealth Technology Ambagon Therapeutics, Inc. provides healthcare services. It specializes in biotechnology. The company is headquartered in San Francisco, CA. | - |
| Karin Kleinhans | M | - |
Merck Research Ventures
Merck Research Ventures Investment ManagersFinance Merck Research Ventures (Merck Research) is a venture capital subsidiary of Merck Research Laboratories Massachusetts LLC founded in 2000. The firm is headquartered in Cambridge, Massachusetts. | 22 years |
| Alan Ashworth | M | 63 |
Ambagon Therapeutics, Inc.
Ambagon Therapeutics, Inc. BiotechnologyHealth Technology Ambagon Therapeutics, Inc. provides healthcare services. It specializes in biotechnology. The company is headquartered in San Francisco, CA. | - |
| Adam Rosenberg | M | 54 |
Ambagon Therapeutics, Inc.
Ambagon Therapeutics, Inc. BiotechnologyHealth Technology Ambagon Therapeutics, Inc. provides healthcare services. It specializes in biotechnology. The company is headquartered in San Francisco, CA. | - |
| Steven Gillis | M | 71 |
Mozart Therapeutics, Inc.
Mozart Therapeutics, Inc. BiotechnologyHealth Technology Mozart Therapeutics, Inc. is a company focused on developing first-in-class disease-modifying therapies for autoimmune and inflammatory diseases, with a therapeutic focus on autoimmune mediated gastro-intestinal disorders. The company is based in Seattle, WA. The company utilizes a novel approach to restoring immune system function by targeting the CD8 T regulatory network. Mozart Therapeutics is advancing a pipeline of first-in-class ‘CD8 Treg modulators’ designed to restore durable immune balance. The CEO of the company is Katie Fanning. | - |
| Helen Kim | F | 61 |
InduPro, Inc.
InduPro, Inc. BiotechnologyHealth Technology InduPro, Inc. engages in integrating inherent protein proximity at the cell surface and translates biological insights into transformative therapeutics. The company is based in San Francisco, CA. The company was founded by K. Christopher Garcia. | 2 years |
| Corey Goodman | M | 72 |
Tallac Therapeutics, Inc.
Tallac Therapeutics, Inc. BiotechnologyHealth Technology Tallac Therapeutics, Inc. engages in the development of immunomodulating polynucleotides. The company is headquartered in Burlingame, CA. | - |
| Thomas Daniel | M | 70 |
Mozart Therapeutics, Inc.
Mozart Therapeutics, Inc. BiotechnologyHealth Technology Mozart Therapeutics, Inc. is a company focused on developing first-in-class disease-modifying therapies for autoimmune and inflammatory diseases, with a therapeutic focus on autoimmune mediated gastro-intestinal disorders. The company is based in Seattle, WA. The company utilizes a novel approach to restoring immune system function by targeting the CD8 T regulatory network. Mozart Therapeutics is advancing a pipeline of first-in-class ‘CD8 Treg modulators’ designed to restore durable immune balance. The CEO of the company is Katie Fanning. | 4 years |
| Ion Stancu | M | 74 |
University of Geneva
| 19 years |
| Nancy Hong | M | - |
Xilio Therapeutics LLC
Xilio Therapeutics LLC Pharmaceuticals: MajorHealth Technology Part of Xilio Therapeutics, Inc., Xilio Therapeutics LLC develops cancer biopharmaceuticals. The company is based in Waltham, MA. The CEO of the company is René Russo. | 4 years |
| Timothy Kutzkey | M | 49 |
InduPro, Inc.
InduPro, Inc. BiotechnologyHealth Technology InduPro, Inc. engages in integrating inherent protein proximity at the cell surface and translates biological insights into transformative therapeutics. The company is based in San Francisco, CA. The company was founded by K. Christopher Garcia. | - |
| Jayson Punwani | M | - |
Xilio Therapeutics LLC
Xilio Therapeutics LLC Pharmaceuticals: MajorHealth Technology Part of Xilio Therapeutics, Inc., Xilio Therapeutics LLC develops cancer biopharmaceuticals. The company is based in Waltham, MA. The CEO of the company is René Russo. | 4 years |
| Cristina Csimma | M | 65 |
Caraway Therapeutics, Inc.
Caraway Therapeutics, Inc. BiotechnologyHealth Technology Caraway Therapeutics, Inc. provides heathcare services. The company was founded by Timothy Harris, Wade Harper ,Ivan Dikic ,Tony Hyman and is headquartered in Cambridge, MA. | 5 years |
| Roel Bulthuis | M | - |
Ambagon Therapeutics, Inc.
Ambagon Therapeutics, Inc. BiotechnologyHealth Technology Ambagon Therapeutics, Inc. provides healthcare services. It specializes in biotechnology. The company is headquartered in San Francisco, CA. | 5 years |
| Henrijette Richter | M | 53 |
Mozart Therapeutics, Inc.
Mozart Therapeutics, Inc. BiotechnologyHealth Technology Mozart Therapeutics, Inc. is a company focused on developing first-in-class disease-modifying therapies for autoimmune and inflammatory diseases, with a therapeutic focus on autoimmune mediated gastro-intestinal disorders. The company is based in Seattle, WA. The company utilizes a novel approach to restoring immune system function by targeting the CD8 T regulatory network. Mozart Therapeutics is advancing a pipeline of first-in-class ‘CD8 Treg modulators’ designed to restore durable immune balance. The CEO of the company is Katie Fanning. | - |
| K. Christopher Garcia | M | - |
Mozart Therapeutics, Inc.
Mozart Therapeutics, Inc. BiotechnologyHealth Technology Mozart Therapeutics, Inc. is a company focused on developing first-in-class disease-modifying therapies for autoimmune and inflammatory diseases, with a therapeutic focus on autoimmune mediated gastro-intestinal disorders. The company is based in Seattle, WA. The company utilizes a novel approach to restoring immune system function by targeting the CD8 T regulatory network. Mozart Therapeutics is advancing a pipeline of first-in-class ‘CD8 Treg modulators’ designed to restore durable immune balance. The CEO of the company is Katie Fanning. | - |
| Margarita I. Chavez | F | - |
Ambagon Therapeutics, Inc.
Ambagon Therapeutics, Inc. BiotechnologyHealth Technology Ambagon Therapeutics, Inc. provides healthcare services. It specializes in biotechnology. The company is headquartered in San Francisco, CA. | - |
| James Joseph Graziano | M | 56 |
InduPro, Inc.
InduPro, Inc. BiotechnologyHealth Technology InduPro, Inc. engages in integrating inherent protein proximity at the cell surface and translates biological insights into transformative therapeutics. The company is based in San Francisco, CA. The company was founded by K. Christopher Garcia. | - |
| Jasmina Marjanovic | F | - |
Mozart Therapeutics, Inc.
Mozart Therapeutics, Inc. BiotechnologyHealth Technology Mozart Therapeutics, Inc. is a company focused on developing first-in-class disease-modifying therapies for autoimmune and inflammatory diseases, with a therapeutic focus on autoimmune mediated gastro-intestinal disorders. The company is based in Seattle, WA. The company utilizes a novel approach to restoring immune system function by targeting the CD8 T regulatory network. Mozart Therapeutics is advancing a pipeline of first-in-class ‘CD8 Treg modulators’ designed to restore durable immune balance. The CEO of the company is Katie Fanning. | 1 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Eugenio Rodriguez | M | - |
University of Geneva
| 9 years |
| Roger Guerra | M | - |
University of Geneva
| 9 years |
| Sebastian Jaimungal | M | - |
University of British Columbia
| 5 years |
| Paul Thomas | M | 50 |
University of British Columbia
| 3 years |
| Helge Seetzen | M | - |
University of British Columbia
| 11 years |
| Nick B. Drake | M | - |
University of British Columbia
| 10 years |
| Wale Bolorunduro | M | - |
University of British Columbia
| 4 years |
| Dravasp Jhabvala | M | - |
University of Geneva
| 6 years |
| Ram Selvaraju | M | 45 |
University of Geneva
| 4 years |
| Steve Veitch | M | - |
University of British Columbia
| 5 years |
| Salim Dhanji | M | 44 |
University of British Columbia
| 8 years |
| Jacqueline Simpson | F | - |
University of British Columbia
| 11 years |
| Robert E. Cohen | M | - |
University of British Columbia
| 11 years |
| Melanie Mackay | F | 49 |
University of British Columbia
| 4 years |
| G. Cameron Dong | M | - |
University of British Columbia
| 4 years |
| Yau Man Hwang | M | 46 |
University of British Columbia
| 4 years |
| Jason Rosychuk | M | 50 |
University of British Columbia
| 1 years |
| Paul Jones | M | - |
University of British Columbia
| 4 years |
| Jason Ladicos | M | - |
University of British Columbia
| 4 years |
| Michael Kelm | M | - |
University of British Columbia
| 4 years |
| Ricky W. Liu | M | - |
University of British Columbia
| 4 years |
| Jessica Lu | F | - |
University of British Columbia
| 4 years |
| Fung Long | M | 43 |
University of British Columbia
| 4 years |
| Eric Jackson Chang | M | 43 |
University of British Columbia
| 4 years |
| Richard Law | M | - |
University of British Columbia
| 4 years |
| Simon Mo | M | - |
University of British Columbia
| 4 years |
| Chris Bruggencate | M | - |
University of British Columbia
| 3 years |
| Matt Lennox-King | M | 47 |
University of British Columbia
| 14 years |
| King Wai Wong | M | 41 |
University of British Columbia
| 4 years |
| Henry Chow | M | 45 |
University of British Columbia
| 4 years |
| Kwong Yuen Chan | M | 67 |
University of British Columbia
| 4 years |
| Simon Fan | M | 43 |
University of British Columbia
| 3 years |
| Kong Lok Yip | M | 48 |
University of British Columbia
| 1 years |
| Michael Forbes | M | 44 |
University of British Columbia
| 4 years |
| Justin Cochrane | M | 44 |
University of British Columbia
| 4 years |
| Gary Thompson | M | 60 |
University of British Columbia
| 4 years |
| Philip Lind | M | 80 |
University of British Columbia
| 3 years |
| Stephen Hui | M | - |
University of British Columbia
| 4 years |
| Chris Li | M | - |
University of British Columbia
| 4 years |
| Dennis Fong | M | - |
University of British Columbia
| 4 years |
| David Kwan | M | - |
University of British Columbia
| 4 years |
| Michael James Craig | M | - |
University of British Columbia
| 4 years |
| Darren Bahrey | M | 57 |
University of British Columbia
| 4 years |
| Anita Algie | F | 43 |
University of British Columbia
| 4 years |
| Cheryl Pate | F | 48 |
University of British Columbia
| 4 years |
| Jennifer Wood | F | - |
University of British Columbia
| 3 years |
| Allan Rajesky | M | - |
University of British Columbia
| 4 years |
| George Choi | M | - |
University of British Columbia
| 4 years |
| Hassan Salari | M | 69 |
University of British Columbia
| 12 years |
| Evelyn Cox | F | - |
University of British Columbia
| 4 years |
| David Mhina McHaina | M | - |
University of British Columbia
| 3 years |
| Cale Moodie | M | 48 |
University of British Columbia
| 4 years |
| Tate Griffith Haggins | M | - |
University of British Columbia
| 4 years |
| Ole Tangermann | M | 47 |
University of British Columbia
| 2 years |
| Ian J. Scott | M | - |
University of British Columbia
| 2 years |
| Benjamin Gelber | M | 45 |
University of British Columbia
| 4 years |
| Matthew Turner | M | - |
University of British Columbia
| 4 years |
| Douglas Smith | M | 61 |
University of British Columbia
| 3 years |
| Danny Hung | M | - |
University of British Columbia
| 4 years |
| Mark Achtemichuk | M | 48 |
University of British Columbia
| 4 years |
| Donna Sadowski | M | - |
University of British Columbia
| 2 years |
| Wendy Foster | F | - |
University of British Columbia
| 7 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Canada | 58 | 58.00% |
| United States | 37 | 37.00% |
| Switzerland | 5 | 5.00% |
| United Kingdom | 0 | -.--% |
| Germany | 0 | -.--% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Peter Dudek
- Personal Network
